Innate Pharma S.A. (IPHYF)
USD 1.45
(-30.62%)
USD 1.45
(-30.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.57 Million EUR | 86.97% |
| 2022 | -58.1 Million EUR | -10.02% |
| 2021 | -52.8 Million EUR | 17.47% |
| 2020 | -63.98 Million EUR | -208.22% |
| 2019 | -20.75 Million EUR | -780.85% |
| 2018 | 3.04 Million EUR | 106.3% |
| 2017 | -48.38 Million EUR | -482.79% |
| 2016 | 12.64 Million EUR | 288.49% |
| 2015 | -6.7 Million EUR | 65.87% |
| 2014 | -19.64 Million EUR | -579.36% |
| 2013 | -2.89 Million EUR | 9.6% |
| 2012 | -3.19 Million EUR | 54.17% |
| 2011 | -6.98 Million EUR | 48.89% |
| 2010 | -13.65 Million EUR | 6.62% |
| 2009 | -14.62 Million EUR | -48.46% |
| 2008 | -9.85 Million EUR | -10.47% |
| 2007 | -8.91 Million EUR | -47.6% |
| 2006 | -6.04 Million EUR | 1.42% |
| 2005 | -6.12 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -12.38 Million EUR | 0.0% |
| 2024 Q1 | -12.38 Million EUR | -166.62% |
| 2023 Q2 | 1.71 Million EUR | 100.0% |
| 2023 Q3 | -4.64 Million EUR | -370.31% |
| 2023 Q4 | -4.64 Million EUR | 0.0% |
| 2023 FY | -7.57 Million EUR | 86.97% |
| 2023 Q1 | 859 Thousand EUR | 101.33% |
| 2022 FY | -58.1 Million EUR | -10.02% |
| 2022 Q2 | 6.3 Million EUR | 97.71% |
| 2022 Q1 | 3.18 Million EUR | 110.96% |
| 2022 Q4 | -64.4 Million EUR | -100.18% |
| 2022 Q3 | -32.17 Million EUR | -610.46% |
| 2021 Q2 | -23.71 Million EUR | -171.54% |
| 2021 Q3 | -14 Million EUR | 40.96% |
| 2021 Q4 | -29.09 Million EUR | -107.73% |
| 2021 FY | -52.8 Million EUR | 17.47% |
| 2021 Q1 | -8.73 Million EUR | 83.72% |
| 2020 Q4 | -53.65 Million EUR | -100.0% |
| 2020 Q1 | -5.16 Million EUR | 84.8% |
| 2020 Q2 | -10.33 Million EUR | -100.0% |
| 2020 Q3 | -26.82 Million EUR | -159.58% |
| 2020 FY | -63.98 Million EUR | -208.22% |
| 2019 Q2 | 13.24 Million EUR | 100.0% |
| 2019 Q1 | 6.62 Million EUR | -27.12% |
| 2019 Q3 | -16.99 Million EUR | -228.4% |
| 2019 Q4 | -33.99 Million EUR | -100.0% |
| 2019 FY | -20.75 Million EUR | -780.85% |
| 2018 Q2 | -7.55 Million EUR | 0.0% |
| 2018 FY | 3.04 Million EUR | 106.3% |
| 2018 Q1 | -7.55 Million EUR | 39.59% |
| 2018 Q4 | 9.08 Million EUR | 0.0% |
| 2018 Q3 | 9.08 Million EUR | 220.17% |
| 2017 Q2 | -11.67 Million EUR | 0.0% |
| 2017 FY | -48.38 Million EUR | -482.79% |
| 2017 Q4 | -12.51 Million EUR | 0.0% |
| 2017 Q3 | -12.51 Million EUR | -7.14% |
| 2017 Q1 | -11.67 Million EUR | -247.74% |
| 2016 FY | 12.64 Million EUR | 288.49% |
| 2016 Q1 | -1.58 Million EUR | -340.23% |
| 2016 Q2 | -1.58 Million EUR | 0.0% |
| 2016 Q3 | 7.9 Million EUR | 598.61% |
| 2016 Q4 | 7.9 Million EUR | 0.0% |
| 2015 FY | -6.7 Million EUR | 65.87% |
| 2015 Q4 | 660 Thousand EUR | 0.0% |
| 2015 Q3 | 660 Thousand EUR | 116.45% |
| 2015 Q2 | -4.01 Million EUR | 0.0% |
| 2015 Q1 | -4.01 Million EUR | 24.34% |
| 2014 Q1 | -4.51 Million EUR | -1488.58% |
| 2014 FY | -19.64 Million EUR | -579.36% |
| 2014 Q4 | -5.3 Million EUR | 0.0% |
| 2014 Q3 | -5.3 Million EUR | -17.36% |
| 2014 Q2 | -4.51 Million EUR | 0.0% |
| 2013 Q4 | -284.5 Thousand EUR | 0.0% |
| 2013 Q3 | -284.5 Thousand EUR | 75.51% |
| 2013 Q1 | -1.16 Million EUR | -97.2% |
| 2013 FY | -2.89 Million EUR | 9.6% |
| 2013 Q2 | -1.16 Million EUR | 0.0% |
| 2012 Q3 | -589 Thousand EUR | 0.0% |
| 2012 Q4 | -589 Thousand EUR | 0.0% |
| 2012 FY | -3.19 Million EUR | 54.17% |
| 2011 FY | -6.98 Million EUR | 48.89% |
| 2010 FY | -13.65 Million EUR | 6.62% |
| 2009 FY | -14.62 Million EUR | -48.46% |
| 2008 FY | -9.85 Million EUR | -10.47% |
| 2007 FY | -8.91 Million EUR | -47.6% |
| 2006 FY | -6.04 Million EUR | 1.42% |
| 2005 FY | -6.12 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | -98.219% |
| Skye Bioscience, Inc. | -37.64 Million USD | 79.891% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 111.622% |
| Nascent Biotech, Inc. | -2.08 Million USD | -262.603% |
| Qrons Inc. | -789.34 Thousand USD | -859.021% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 10.763% |
| CSL Limited | 2.64 Billion USD | 100.287% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 114.289% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -8.409% |
| Regen BioPharma, Inc. | 1.02 Million USD | 839.613% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 87.907% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1721.993% |
| Rebus Holdings, Inc. | -1.02 Million USD | -642.157% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -466.858% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1097.014% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 52.304% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 89.902% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -15.114% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2668.817% |
| SQZ Biotechnologies Company | -79.46 Million USD | 90.474% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -161.721% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -315.813% |
| Mesoblast Limited | -87.95 Million USD | 91.393% |
| Marizyme, Inc. | -65.34 Million USD | 88.416% |
| Genus plc | 7.9 Million USD | 195.823% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 30.498% |
| Pharming Group N.V. | -10.54 Million USD | 28.233% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -248.878% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -104.03% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 14.405% |
| ContraFect Corporation | -65.15 Million USD | 88.381% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -54.93% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -338.217% |
| IMV Inc. | -36.48 Million USD | 79.252% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 6.076% |
| MultiCell Technologies, Inc. | -380.07 USD | -1991638.364% |
| ONE Bio Corp. | 8.67 Million USD | 187.246% |
| Accustem Sciences Inc. | -3.74 Million USD | -102.06% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 85.356% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -497.411% |
| Q BioMed Inc. | -2.05 Million USD | -268.892% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -102.786% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -217.951% |
| Biomind Labs Inc. | -1.21 Million USD | -523.395% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 87.325% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -144.054% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 4.215% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -288.355% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -50447.543% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -30.13% |
| GB Sciences, Inc. | -1.36 Million USD | -455.932% |
| Alpha Cognition Inc. | -13.77 Million USD | 45.036% |
| HST Global, Inc. | -146.21 Thousand USD | -5077.484% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -331.395% |
| Halberd Corporation | -79.67 Thousand USD | -9400.979% |
| Enzolytics Inc. | -2.17 Million USD | -247.753% |
| Agentix Corp. | -1.37 Million USD | -450.862% |
| Resverlogix Corp. | -3.61 Million USD | -109.695% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -138.693% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.434% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 7824.49% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 209.32% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -90.536% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -150.154% |
| AVAX Technologies, Inc. | -6.41 Million USD | -18.03% |
| Zenith Capital Corp. | -10.59 Million USD | 28.558% |
| Genscript Biotech Corporation | -95.47 Million USD | 92.071% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -32470.347% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -82.588% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -12424.692% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -277.534% |
| Kadimastem Ltd | -3.3 Million USD | -128.881% |
| Helix BioMedix, Inc. | -1.05 Million USD | -616.817% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1615.118% |
| LadRx Corporation | 400.44 Thousand USD | 1990.406% |
| Cell Source, Inc. | -5.32 Million USD | -42.261% |
| Regen BioPharma, Inc. | 1.02 Million USD | 839.613% |
| NovAccess Global Inc. | -4.76 Million USD | -58.727% |
| Affymax, Inc. | -14.42 Million USD | 47.518% |
| Itoco Inc. | -1.86 Million USD | -305.031% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -70.398% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -353.565% |
| Mobile Lads Corp. | -2.26 Million USD | -234.469% |
| CytoDyn Inc. | -49.84 Million USD | 84.812% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -9478.277% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -3218.327% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -704.011% |
| SYBLEU INC | -180.3 Thousand USD | -4098.465% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -369.388% |
| International Stem Cell Corporation | -131 Thousand USD | -5678.626% |
| Bioxytran, Inc. | -4.28 Million USD | -76.869% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -13848.261% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -199.18% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 84.253% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -258.089% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -869.41% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -138.952% |
| Neutra Corp. | -233.46 Thousand USD | -3142.456% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 62.693% |
| PureTech Health plc | -65.69 Million USD | 88.477% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 64.404% |
| IXICO plc | -1.17 Million USD | -542.615% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 23.743% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 86.749% |
| CSL Limited | 2.64 Billion USD | 100.287% |
| Cellectis S.A. | -103.17 Million USD | 92.663% |